Diclofenac
Class
Antipyretic/analgesic NSAID
Indications
pain
dysmenorrhea
ocular inflammation
osteoarthritis
rheumatoid arthritis
ankylosing spondylitis
actinic keratosis
Administration/Absorption
Completely absorbed from the gastrointestinal tract
Topical cream
Dosage
Distribution
Mechanism
2-(2,6-dichloranilino) phenylacetic acid
The most potent NSAID on a broad basis
COX-1 and COX-2 inhibition
=> peripheral inhibition of prostaglandin synthesis
Approximately 10-fold for the COX2-isoenzyme
Somewhat lower incidence of gastrointestinal complaints than noted with indomethacin and aspirin
Inhibition of leukocyte migration
Antipyretic effects may be due to action on the hypothalamus, resulting in peripheral dilation, increased cutaneous blood flow, and subsequent heat dissipation
There is some evidence that diclofenac inhibits the lipoxygenase pathways thus reducing formation of the leukotrienes
There is also speculation that diclofenac may inhibit phospholipase A2
Excretion
The action of one single dose is much longer (6 to 8 hours) than the very short half-life that the drug indicates
This could be partly because it persists for over 11 hours in synovial fluids
Side effects
Interactions
Contraindications
Hypersensitivity against diclofenac
History of allergic reactions (bronchospasm, shock, rhinitis, urticaria) following the use of Aspirin or another NSAID
Active stomach and/or duodenal ulceration or gastrointestinal bleeding
Inflammative intestinal disorders such as Crohn's disease or ulcerative colitis
Severe insufficiency of the heart (NYHA III/IV)
Recently, a warning has been issued by FDA not to use to treat patients recovering from heart surgery
Severe liver insufficiency (Child-Pugh Class C)
Severe renal insufficiency (creatinine clearance <30 ml/min)
Caution in patients with preexisting hepatic porphyria, as diclofenac may trigger attacks
Caution in patients with severe, active bleeding such as cerebral hemorrhage
NSAIDs in general should be avoided during dengue fever.